|
| 產(chǎn)地 | 進(jìn)口、國(guó)產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS10759 |
| 應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-phospho-PRKCZ(Thr500) |
| 克隆性 | |
| 靶點(diǎn) | 詳見(jiàn)說(shuō)明書(shū) |
| 適應(yīng)物種 | 詳見(jiàn)說(shuō)明書(shū) |
| 形態(tài) | 詳見(jiàn)說(shuō)明書(shū) |
| 宿主 | 詳見(jiàn)說(shuō)明書(shū) |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見(jiàn)說(shuō)明書(shū) |
| 濃度 | 1mg/1ml% |
| 免疫原 | LH conjugated Synthesised phosphopeptide derived from human PRKCZ around the phosphorylation site of Thr500 |
產(chǎn)品訂購(gòu)信息：
英文名稱 Anti-phospho-PRKCZ(Thr500)
中文名稱 磷酸化蛋白激酶C(T500)抗體品牌
別 名 PRKCZ(phospho T500); rotein Kinase C; AAG6; Aging associated gene 6; MGC129900; MGC129901; MGC41878; MGC57564; PKC B; PKC beta; PKC zeta; PKC2; PKCB; PKCC; PKCD; PKCE; PKCG; PRKACA; PRKC A; PRKC G; PRKCA; PRKCB; PRKCB1; PRKCB2; PRKCD; PRKCE; PRKCG; PRKCZ ; Protein kinase C alpha; Protein kinase C alpha type; Protein Kinase C; Protein kinase C beta 1; Protein kinase C beta 1 polypeptide; Protein kinase C beta; Protein kinase C beta type; Protein kinase C delta; Protein kinase C epsilon; Protein kinase C gamma; Protein kinase C gamma type; Protein kinase C zeta; SCA14; Spinocerebellar ataxia 14; KPCB_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Chicken, Cow, Horse, Rabbit
產(chǎn)品類型 一抗 磷酸化抗體
研究領(lǐng)域 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 細(xì)胞凋亡 激酶和磷酸酶
蛋白分子量 predicted molecular weight: 77kDa
性 狀 Lyophilized or Liquid
免 疫 原 LH conjugated Synthesised phosphopeptide derived from human PRKCZ around the phosphorylation site of Thr500
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
磷酸化蛋白激酶C(T500)抗體品牌 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases that can be activated by calcium and second messenger diacylglycerol. PKC family members phosphorylate a wide variety of protein targets and are known to be involved in diverse cellular signaling pathways. PKC family members also serve as major receptors for phorbol esters, a class of tumor promoters. Each member of the PKC family has a specific expression profile and is believed to play a distinct role in cells. The protein encoded by this gene is one of the PKC family members. This protein kinase has been reported to be involved in many different cellular functions, such as B cell activation, apoptosis induction, endothelial cell proliferation, and intestinal sugar absorption. Studies in mice also suggest that this kinase may also regulate neuronal functions and correlate fear-induced conflict behavior after stress. Alternatively spliced transcript variants encoding distinct isoforms have been reported.
Function : Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase involved in various cellular processes such as regulation of the B-cell receptor (BCR) signalosome, oxidative stress-induced apoptosis, androgen receptor-dependent transcription regulation, insulin signaling and endothelial cells proliferation. Plays a key role in B-cell activation by regulating BCR-induced NF-kappa-B activation. Mediates the activation of the canonical NF-kappa-B pathway (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559', 'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1 association with lipid rafts and recruitment of the BCL10-MALT1 complex as well as MAP3K7/TAK1, which then activates IKK complex, resulting in nuclear translocation and activation of NFKB1. Plays a direct role in the negative feedback regulation of the BCR signaling, by down-modulating BTK function via direct phosphorylation of BTK at 'Ser-180', which results in the alteration of BTK plasma membrane localization and in turn inhibition of BTK activity. Involved in apoptosis following oxidative damage: in case of oxidative conditions, specifically phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to mitochondrial accumulation of p66Shc, where p66Shc acts as a reactive oxygen species producer. Acts as a coactivator of androgen receptor (ANDR)-dependent transcription, by being recruited to ANDR target genes and specifically mediating phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag for epigenetic transcriptional activation that prevents demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In insulin signaling, may function downstream of IRS1 in muscle cells and mediate insulin-dependent DNA synthesis through the RAF1-MAPK/ERK signaling cascade. May participate in the regulation of glucose transport in adipocytes by negatively modulating the insulin-stimulated translocation of the glucose transporter SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is probably involved in the inhibition of the insulin gene transcription, via regulation of MYC expression. In endothelial cells, activation of PRKCB induces increased phosphorylation of RB1, increased VEGFA-induced cell proliferation, and inhibits PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by insulin, which causes endothelial dysfunction. Also involved in triglyceride homeostasis (By similarity).
Subunit : Interacts with PDK1 (By similarity). Interacts in vitro with PRKCBP1. Interacts with PHLPP1 and PHLPP2; both proteins mediate its dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and ANDR.
Subcellular Location : Cytoplasm. Nucleus. Membrane; Peripheral membrane protein.
Similarity : Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. PKC subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 C2 domain.
Contains 2 phorbol-ester/DAG-type zinc fingers.
Contains 1 protein kinase domain.
Database links : UniProtKB/Swiss-Prot: P05771.4
Anti- Beta-catenin/ Beta-cats /FITC 熒光素標(biāo)記 β-連環(huán)蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-HCMV UL23/HHV5 UL23/FITC 熒光素標(biāo)記人巨細(xì)胞病毒UL23抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh Centaurin γ1 中心體肌動(dòng)蛋白γ1抗體(增強(qiáng)型PI3K蛋白) 規(guī)格 0.2ml
Tie2(Porcine tyrosine kinase with immunoglobulin-like and EGF-like domains 2) 上皮生長(zhǎng)因子樣域酪酸激酶2抗原 0.5mg
IGF1R 英文名稱： 樣生長(zhǎng)因子1受體抗體 0.1ml
Rhesus antibody Rh TIS11D/ERF2 表皮生長(zhǎng)因子反應(yīng)蛋白2抗體 規(guī)格 0.2ml
Anti-HCMV UL23/HHV5 UL23/FITC 熒光素標(biāo)記人巨細(xì)胞病毒UL23抗體IgGMulti-class antibodies規(guī)格： 0.2ml
HB- Beta(Human Beta-subunits of hemoglobin) ELISA Kit 人血紅蛋白β亞基Multi-class antibodies規(guī)格： 48T
Anti-Phospho-RasGRF1 (Ser916) 磷酸化Ras特異性鳥(niǎo)嘌呤核苷酸釋放因子1Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh HA tag HA tag標(biāo)簽抗體 規(guī)格 0.1ml
MUC5AC(Human Mucin-5 subtype AC) ELISA Kit 人粘蛋白/粘液素5AC 96T
PRR15 英文名稱： 富含脯酸蛋白15抗體 0.2ml
BTNL8 英文名稱： 嗜乳脂蛋白樣8抗體 0.2ml
Anti-Phospho-RasGRF1 (Ser916) 磷酸化Ras特異性鳥(niǎo)嘌呤核苷酸釋放因子1Multi-class antibodies規(guī)格： 0.1ml
IL-4 ELISA KIT 大鼠白介素4Multi-class antibodies規(guī)格： 48T
Anti-p-BAD/FITC 熒光素標(biāo)記抗磷酸化相關(guān)死亡促進(jìn)因子p-BAD抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh ETK/BMX 非受體性蛋白酪氨酸激酶ETK抗體 規(guī)格 0.1ml
IAP(Human inhibitor of apoptosis) ELISA Kit 人細(xì)胞凋亡抑制因子 96T
Phospho-MYPT1 (Ser507) 英文名稱： 磷酸化肌球蛋酸酶抗體 0.1ml
Angiotensin II 英文名稱： 緊張素Ⅱ抗體 0.1ml
Anti-p-BAD/FITC 熒光素標(biāo)記抗磷酸化相關(guān)死亡促進(jìn)因子p-BAD抗體IgGMulti-class antibodies規(guī)格： 0.2ml
CL-00074T1(小鼠癌細(xì)胞)5×106cells/瓶×2
EFNA5 Others Rat 大鼠 Ephrin-A5 / EFNA5 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
小鼠細(xì)胞完全培養(yǎng)基 100mL
TM3小鼠間質(zhì)細(xì)胞 TM3 mouse Leydig cells D-MEM/F-12培養(yǎng)基(GIBCO)+5%馬血清+2.5%FBS
IL20 Protein Human 重組人 IL20 / Ierleukin-20 蛋白
SNU-5(人細(xì)胞) 5×106cells/瓶×2 293(轉(zhuǎn)染腺病毒E1A基因的人腎上皮細(xì)胞)
CL-000422RV1(人細(xì)胞)5×106cells/瓶×2
FKBP14 Others Human 人 FKBP14 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
尿道上皮細(xì)胞生長(zhǎng)添加物UCGS
HEC-1-A細(xì)胞，人子宮內(nèi)膜腺癌細(xì)胞 鼠雜交細(xì)胞,K6H6/B5細(xì)胞 新生兒細(xì)胞Many types of cells包裝：5 × 105次方(1ml)
FC33(人胚胎腎細(xì)胞(Asp-2基因修飾)) 5×106cells/瓶×2
HWP subcutaneous Pellet 人類皮下白前脂肪細(xì)胞團(tuán)塊 > 1 mio.cells 人少突膠質(zhì)前體細(xì)胞(懸浮生長(zhǎng))總RNAHOPC-os NA
磷酸化蛋白激酶C(T500)抗體品牌 PDHA1 Others Human 人 PDHA1 / C54G1 (aa 30-390) 桿狀病毒-昆蟲(chóng)細(xì)胞裂解液 (陽(yáng)性對(duì)照)
CM-H111人成骨細(xì)胞完全培養(yǎng)基100mL
人腎上腺皮質(zhì)細(xì)胞HACC
非洲綠猴腎細(xì)胞系/IgR;VERO/IgR 大鼠細(xì)胞，CBRH-7919細(xì)胞 BEL-7405(細(xì)胞)
人癌細(xì)胞;MCF7
TNFRSF4 Others Human 人 TNFRSF4 / CD134 人細(xì)胞裂解液 (陽(yáng)性對(duì)照)
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 磷酸化蛋白激酶C(T500)抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）磷酸化蛋白激酶C(T500)抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol?？贵w親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
